©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2025; 31(25): 107865
Published online Jul 7, 2025. doi: 10.3748/wjg.v31.i25.107865
Published online Jul 7, 2025. doi: 10.3748/wjg.v31.i25.107865
From scRNA-seq to therapeutic targets: Unveiling the impact of activated mast cells on intestinal dysfunction in acute pancreatitis
Bin Li, Institution of Compared Medicine, Yangzhou University, Yangzhou 225009, Jiangsu Province, China
Bin Li, Center for Integrative Physiology and Molecular Medicine, University of Saarland, Homburg 66424, Saarland, Germany
Author contributions: Li B wrote and edited the manuscript.
Supported by the Top-level Talents Support Program of Yangzhou University; “Lv Yang Jin Feng” Outstanding Doctor of Yangzhou; and Natural Science Foundation of Jiangsu Province, No. BK20240907.
Conflict-of-interest statement: Dr. Li report no relevant conflicts of interest for this article.
Corresponding author: Bin Li, PhD, Full Professor, Institution of Compared Medicine, Yangzhou University, No. 88 South Daxue Road, Yangzhou 225009, Jiangsu Province, China.
Received: April 8, 2025
Revised: April 28, 2025
Accepted: June 16, 2025
Published online: July 7, 2025
Processing time: 87 Days and 20.9 Hours
Revised: April 28, 2025
Accepted: June 16, 2025
Published online: July 7, 2025
Processing time: 87 Days and 20.9 Hours
Core Tip
Core Tip: Applying advanced single-cell transcriptomics, Wei et al’s study elucidates the cellular heterogeneity of the intestine during early acute pancreatitis (AP) and identifies activated mast cells and their CCL5 secretion which are key contributors to gut barrier disruption. These findings provide novel insights into AP pathophysiology and highlight potential avenues for targeted therapeutic interventions. Moreover, the study under